BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Jonathan Salkin Named Executive Vice President of Devicor Medical Products


5/5/2009 11:45:38 AM

Salkin joins former colleague Tom Daulton to provide strategic leadership as Devicor looks to make its first major acquisition

PLEASANT PRAIRIE, Wis., May 5 /PRNewswire/ -- Devicor Medical Products, LLC, today named Jonathan Salkin to serve as Executive Vice President, Corporate Development & Strategy. Salkin's most recent experience as a Managing Director at the Royal Bank of Scotland plc is highlighted by his successful launch of that Bank's first healthcare investment banking group globally. Prior to that, as Vice President of Corporate Development for Cardinal Health, Salkin was instrumental in strategic planning, mergers and acquisitions for Cardinal's $10 billion Medical Products & Services group.

It was at Cardinal that Salkin first connected with Tom Daulton, Devicor's CEO. "Jon brings the perfect blend of disciplines to Devicor," said Daulton. "His combined experience in the worlds of finance, strategy and healthcare will drive us forward as we work to build a market-leading medical device company."

Based in the New York City area, one of Salkin's primary responsibilities will be to work with Daulton to secure Devicor's initial platform acquisition as the company looks to acquire established interventional medical device businesses that manufacture and sell products to clinicians in settings such as hospitals, surgery centers, or physician offices. Beyond that, Salkin will work on strategic initiatives including subsequent mergers, acquisitions, and other collaborative endeavors; he is expected to take a leadership role in running certain segments of the day-to-day operations; and he'll serve on Devicor's Board of Directors.

"Having previously worked with Tom to successfully build a fast-growing, profitable business, I am thrilled to once again be his partner as Devicor deploys its substantial funding into products and companies that are advancing the field of interventional medicine and lowering overall healthcare costs," Salkin said.

Devicor was formed in partnership with GTCR, one of the nation's leading private equity firms, which plans to invest up to $250 million of equity capital to support the company's strategy.

Salkin previously worked for Dresdner Kleinwort Wasserstein (formerly Wasserstein Perella & Co.) as Director of Healthcare Mergers & Acquisitions, and in the Mergers, Acquisitions and Corporate Advisory Group at Deutsche Bank. He received a BA, MBA, and JD from Case Western Reserve University in Cleveland, Ohio.

About Devicor Medical Products, LLC

Devicor Medical Products, headquartered in Pleasant Prairie, Wisconsin, is a global medical device company focused on acquiring and developing clinical preference medical devices and companies. For more information, please visit www.devicormedical.com or call (262) 857-9300.

About GTCR

Founded in 1980, GTCR Golder Rauner, LLC is a leading private equity investment firm and long-term strategic partner for outstanding management teams. The Chicago-based firm pioneered the investment strategy of identifying and partnering with exceptional executives to acquire and build companies through a combination of acquisitions and strong internal growth. GTCR currently manages more than $8 billion of equity capital invested in a wide range of companies and industries. More information about GTCR can be found at www.gtcr.com.

CONTACT: Maggie Baum of 100 Monkeys, Inc., +1-608-438-2814,
mbaum@100monkeyspr.com, for Devicor Medical Products, LLC

Web site: http://www.devicormedical.com/
http://www.gtcr.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES